Spots Global Cancer Trial Database for Efficacy and Safety Study of Sorafenib Plus Pravastatin to Treat Advanced Hepatocarcinoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Efficacy and Safety Study of Sorafenib Plus Pravastatin to Treat Advanced Hepatocarcinoma
Official Title: Phase-II, Multicenter, Randomized, Double-Blind, Parallel-Group Trial to Compare the Efficacy and Safety of Sorafenib Plus Pravastatin Against Sorafenib Plus Placebo in Patients With Advanced Hepatocarcinoma
Study ID: NCT01418729
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to evaluate the overall survival (OS) in order to assess the efficacy and safety of pravastatin as adjuvant treatment to sorafenib.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Hospital Donostia, Instituto Biodonostia, San Sebastian, Gipuzkoa, Spain
Contact Details
Name: Juan I Arenas, MD,PHD
Affiliation: Hospital Donostia
Role: STUDY_CHAIR
Name: Javier Bustamante Scheneider, MD
Affiliation: Hospital de Cruces
Role: PRINCIPAL_INVESTIGATOR
Name: Trinidad Serrano Aullo, MD, PHD
Affiliation: Hospital Clínico Universitario Lozano Blesa
Role: PRINCIPAL_INVESTIGATOR
Name: Mercedes Iñarrairaegui Bastarrica, MD
Affiliation: Clínica Universitaria de Navarra
Role: PRINCIPAL_INVESTIGATOR
Name: Sonia Blanco Sampascual, MD
Affiliation: Hospital de Basurto
Role: PRINCIPAL_INVESTIGATOR
Name: Maria Varela, MD, PHD
Affiliation: Hospital Central de Asturias
Role: PRINCIPAL_INVESTIGATOR
Name: Oscar Nuñez, MD
Affiliation: Hospital Infanta Sofia
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
